Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone Payments
Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40
Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25
Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target
Cartesian Therapeutics shares are trading higher after the company reported its Q4 financial results.
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
